News headlines about Medical Transcription Billing (NASDAQ:MTBC) have been trending positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Medical Transcription Billing earned a media sentiment score of 0.28 on Accern’s scale. Accern also assigned news headlines about the technology company an impact score of 46.1605209164435 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news headlines that may have effected Accern’s rankings:
- MTBC Full Year 2017 Shareholder Update (finance.yahoo.com)
- Medical Transcription Billing (MTBC) Lowered to Hold at Zacks Investment Research (americanbankingnews.com)
- MTBC to Present at the 2018 LIMRA Enrollment Technology Strategy Seminar (finance.yahoo.com)
- Medical Transcription Billing, Corp., (NASDAQ: MTBC) – Investors are Unsure How to React (Brief Analysis) – Stock Watch (stocksnewstimes.com)
- Medical Transcription Billing, Corp. (NASDAQ:MTBC) – What Do Analysts’ Recommend? – Nasdaq Journal (press release) (nasdaqjournal.com)
A number of research analysts have recently commented on the company. Zacks Investment Research raised Medical Transcription Billing from a “sell” rating to a “hold” rating in a report on Wednesday, October 18th. ValuEngine lowered Medical Transcription Billing from a “hold” rating to a “sell” rating in a report on Monday, December 4th. Finally, Chardan Capital raised their price target on Medical Transcription Billing from $2.25 to $2.75 and gave the company a “buy” rating in a report on Tuesday, November 14th.
Medical Transcription Billing (MTBC) traded up $0.08 during trading hours on Tuesday, reaching $2.95. The company had a trading volume of 239,500 shares, compared to its average volume of 234,280. The firm has a market capitalization of $34.02, a price-to-earnings ratio of -2.84 and a beta of 1.79. Medical Transcription Billing has a 1 year low of $0.29 and a 1 year high of $5.44. The company has a current ratio of 1.15, a quick ratio of 1.15 and a debt-to-equity ratio of 0.01.
In other Medical Transcription Billing news, CEO Mahmud Ul Haq acquired 30,000 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was purchased at an average cost of $2.93 per share, for a total transaction of $87,900.00. Following the transaction, the chief executive officer now owns 5,017,070 shares of the company’s stock, valued at approximately $14,700,015.10. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, President Stephen Andrew Snyder sold 50,000 shares of the firm’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $3.18, for a total value of $159,000.00. Following the sale, the president now owns 106,000 shares of the company’s stock, valued at $337,080. The disclosure for this sale can be found here. Company insiders own 53.70% of the company’s stock.
Medical Transcription Billing Company Profile
Medical Transcription Billing, Corp. is a healthcare information technology company that provides an integrated suite of Web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. The Company’s offering, PracticePro, allows healthcare practices with the core software and business services on Software-as-a-Service (SaaS) platform.
Receive News & Ratings for Medical Transcription Billing Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medical Transcription Billing and related companies with MarketBeat.com's FREE daily email newsletter.